{"id":"NCT01854528","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","officialTitle":"A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon a-2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE-II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2014-11","completion":"2015-07","firstPosted":"2013-05-15","resultsPosted":"2016-02-11","lastUpdate":"2018-06-06"},"enrollment":148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267, ABT-333","otherNames":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ABT-333 also known as dasabuvir","Viekira PAK"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Pegylated Interferon a-2a (PegINF)","otherNames":[]},{"type":"DRUG","name":"Telaprevir","otherNames":[]}],"arms":[{"label":"3-DAA/RBV","type":"EXPERIMENTAL"},{"label":"TPV/RBV","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and antiviral activity of 3 direct-acting antiviral agents (DAAs; ABT-450/ritonavir/ABT-267 \\[ABT-450/r/ABT-267; ABT-267 also known as ombitasvir\\] and ABT-333 \\[also known as dasabuvir\\]) plus ribavirin (RBV) compared with telaprevir (TPV) with pegylated interferon/ribavirin (pegIFN/RBV) in patients with chronic hepatitis C virus genotype 1 (HCV GT1) infection without cirrhosis who were previously treated with pegylated interferon/ribavirin (pegIFN/RBV).","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","timeFrame":"12 weeks after the last dose of study drug","effectByArm":[{"arm":"3-DAA/RBV","deltaMin":100,"sd":null},{"arm":"TPV/RBV","deltaMin":66,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26321288"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["HEADACHE","PRURITUS","NAUSEA","ASTHENIA","FATIGUE"]}}